Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

50.12 +0.17 (+0.34%)
Official Closing Price Updated: 7:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,622,907
Open 49.82
Bid (Size) 52.24 (16)
Ask (Size) 52.55 (1)
Prev. Close 49.95
Today's Range 49.72 - 50.55
52wk Range 39.35 - 58.75
Shares Outstanding 2,222,113,553
Dividend Yield 4.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Cobenfy is the first drug to treat the disorder without blocking dopamine. 
Via Investor's Business Daily
Exposures Product Safety

Performance

YTD
-5.00%
-5.00%
1 Month
+4.16%
+4.16%
3 Month
+20.74%
+20.74%
6 Month
-7.58%
-7.58%
1 Year
-13.42%
-13.42%

More News

Read More
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Via Benzinga
Exposures Product Safety
NYSE:BMY Shows Potential for a Breakout.
Via Chartmill
What Analysts Are Saying About Bristol-Myers Squibb Stock
Via Benzinga
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Via Benzinga
Exposures Product Safety
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Via Investor's Business Daily
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Current Report: Bristol-Meyers Squibb (BMY)
Via Talk Markets
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
Via Benzinga
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Via The Motley Fool
Merck Scores Two Key Victories With Keytruda In Women's Cancers
Via Investor's Business Daily
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
From Bristol Myers Squibb
Via Business Wire
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
From Bristol Myers Squibb
Via Business Wire
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.